Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Increases By 29.2%

Fractyl Health, Inc. (NASDAQ:GUTS) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 3,100,000 shares, an increase of 29.2% from the January 31st total of 2,400,000 shares. Currently, 15.1% of the company’s shares are short sold. Based on an average daily trading volume, of 327,700 shares, the days-to-cover ratio is currently 9.5 days.

Insider Buying and Selling at Fractyl Health

In other Fractyl Health news, CEO Harith Rajagopalan sold 90,972 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the completion of the sale, the chief executive officer now owns 491,329 shares of the company’s stock, valued at approximately $894,218.78. This trade represents a 15.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jay David Caplan sold 22,346 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.81, for a total value of $40,446.26. Following the transaction, the insider now directly owns 153,544 shares in the company, valued at $277,914.64. The trade was a 12.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Nuveen Asset Management LLC lifted its position in Fractyl Health by 61.5% during the fourth quarter. Nuveen Asset Management LLC now owns 72,958 shares of the company’s stock valued at $150,000 after purchasing an additional 27,778 shares during the last quarter. Blackstone Inc. purchased a new stake in Fractyl Health in the fourth quarter worth approximately $212,000. 683 Capital Management LLC grew its position in Fractyl Health by 4.0% during the fourth quarter. 683 Capital Management LLC now owns 650,000 shares of the company’s stock valued at $1,339,000 after acquiring an additional 25,000 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Fractyl Health by 125.8% during the fourth quarter. Jane Street Group LLC now owns 22,700 shares of the company’s stock worth $47,000 after acquiring an additional 12,648 shares in the last quarter. Finally, Silverarc Capital Management LLC raised its stake in shares of Fractyl Health by 6.2% during the fourth quarter. Silverarc Capital Management LLC now owns 176,922 shares of the company’s stock worth $364,000 after acquiring an additional 10,256 shares in the last quarter.

Fractyl Health Stock Performance

Shares of NASDAQ:GUTS traded down $0.02 during mid-day trading on Thursday, reaching $1.57. The company had a trading volume of 220,511 shares, compared to its average volume of 306,588. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The company’s 50-day moving average price is $1.76 and its 200-day moving average price is $2.27. Fractyl Health has a one year low of $1.37 and a one year high of $9.66. The firm has a market cap of $75.52 million and a price-to-earnings ratio of -0.13.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). As a group, equities research analysts anticipate that Fractyl Health will post -1.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reduced their target price on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.